Get an alert when HUMA THERAPEUTICS LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-29 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-12-09 (in 7mo)

Last made up 2025-11-25

Watchouts

1 item

Cash

£12M

+3.3% vs 2023

Net assets

£71M

-12.5% vs 2023

Employees

337

-9.2% vs 2023

Profit before tax

-£29M

+48.9% vs 2023

Watchouts

Facts from the Companies House register and the latest accounts — not a rating

Accounts

7-year trend · latest reflected 2024-12-31

Metric Trend 2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Turnover £30,695,000£30,074,000
Operating profit -£56,281,000-£29,186,000
Profit before tax -£28,112,000-£56,067,000-£28,664,000
Net profit -£53,046,000-£28,780,000
Cash £5,248,000£44,407,000£11,549,000£11,933,000
Total assets less current liabilities £86,854,000£75,951,000
Net assets £81,544,000£71,387,000
Equity £32,489,000£22,370,000£21,284,000£73,991,000-£99,750,000£81,544,000£71,387,000
Average employees 170371337
Wages £31,766,000£20,138,000
Directors' remuneration £160,000£139,000

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating margin -183.4%-97.0%
Net margin -172.8%-95.7%
Return on capital employed -64.8%-38.4%
Gearing (liabilities / total assets) 18.7%26.5%
Current ratio 3.00x1.81x
Interest cover -157.21x-208.47x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Name history

Renamed 2 times since incorporation

  1. HUMA THERAPEUTICS LIMITED 2020-04-17 → present
  2. HUMAFORHEALTH LIMITED 2020-04-16 → 2020-04-17
  3. MEDOPAD LTD 2011-08-02 → 2020-04-16

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Consolidated group
Auditor
Gravita Audit II Limited
Audit opinion
Qualified
Going concern
Affirmed

“The directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Accordingly they continue to adopt the going concern basis of accounting in preparing the annual financial statements.”

Group structure

  1. HUMA THERAPEUTICS LIMITED · parent
    1. Medopad Inc. 100% · New York, NY · Global health:ech company
    2. Medopad Information Technology (Shanghai) Co., Ltd. 100% · Shanghai · Global health:ech company
    3. Huma Therapeutics GmbH 100% · Germany · Global health:ech company
    4. Iplato Limited 100% · London · Global health:ech company
    5. Iplato Healthcare Limited 100% · London · Global health:ech company
    6. Iplato s.r.o 100% · Pardubice · Global health:ech company
    7. Alcedis GmbH 100% · Germany · Global health:ech company
    8. TheraOp GmbH 100% · Germany · Global health:ech company
    9. eConsult Health Limited 100% · United Kingdom · Global health:ech company
    10. MyMed Ltd 100% · United Kingdom · Global health:ech company

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 6 resigned

Name Role Appointed Born Nationality
KHATIB, Rich, Dr Director 2012-08-01 Dec 1964 British
MALEKI, Eskandar Director 2018-03-07 Dec 1950 Austrian
VAHDAT, Danoosh Director 2012-08-01 Aug 1984 British
Show 6 resigned officers
Name Role Appointed Resigned
FLETCHER, Stuart Robert Director 2017-12-27 2023-10-17
MACKINNON, Simon John Director 2017-10-25 2020-09-23
MILBURN, Alan Director 2020-04-08 2023-10-17
OXLEY, Mark Director 2011-08-02 2012-08-01
SUESSMUTH-DYCKERHOFF, Claudia Ricarda Rita, Dr Director 2021-04-01 2023-10-17
@UKPLC CLIENT DIRECTOR LTD Corporate Director 2011-08-02 2012-08-01

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Mr Danoosh Vahdat Individual Appoints directors 2020-04-09 Active
Mr Danoosh Vahdat Individual Shares 25–50%, Voting 25–50% 2016-05-12 Ceased 2019-01-17
Dr Rich Khatib Individual Shares 25–50%, Voting 25–50% 2016-05-12 Ceased 2019-01-17

Filing timeline

Last 20 of 172 total filings

Date Type Category Description
2025-12-10 CS01 confirmation-statement Confirmation statement with updates PDF
2025-12-01 PSC04 persons-with-significant-control Change to a person with significant control PDF
2025-10-23 AA accounts Accounts with accounts type group PDF
2025-07-23 PSC04 persons-with-significant-control Change to a person with significant control PDF
2025-07-21 SH01 capital Capital allotment shares PDF
2025-07-21 SH01 capital Capital allotment shares PDF
2025-04-11 AA accounts Accounts with accounts type group
2025-03-19 SH01 capital Capital allotment shares PDF
2025-03-19 SH01 capital Capital allotment shares PDF
2025-01-30 MR04 mortgage Mortgage satisfy charge full PDF
2024-12-23 AA01 accounts Change account reference date company previous shortened PDF
2024-11-26 CS01 confirmation-statement Confirmation statement with updates PDF
2024-10-04 SH01 capital Capital allotment shares PDF
2024-10-04 SH01 capital Capital allotment shares PDF
2024-09-27 AA01 accounts Change account reference date company previous shortened PDF
2024-04-29 SH01 capital Capital allotment shares PDF
2024-04-29 SH01 capital Capital allotment shares PDF
2024-04-15 RP04CS01 confirmation-statement Second filing of confirmation statement with made up date
2024-04-15 RP04CS01 confirmation-statement Second filing of confirmation statement with made up date
2023-11-29 CS01 confirmation-statement Confirmation statement with updates

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
6

last 12 months

Capital events
6

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page